Decision Resources, Inc., Dec 2006, Pages: 21
for growth does each of these treatment areas contain? Which area holds the most growth potential? What are some of the roadblocks to new treatment development? GlaxoSmithKline’s first patent on Imitrex
Jain PharmaBiotech, Feb 2012, Pages: 281
for developing markets for transdermal drug delivery
- A selected bibliography of 200 publications
- Text is supplemented by 18 tables and 10 figures
Who should read this report?
- Biotechnology companies
Greystone Associates, March 2009, Pages: 180
- Analyzes patch designs, technologies and patch development issues
- Profiles patch manufacturers and third-party transdermal supply chain (ecosystem) companies
- Provides detailed assessments of more than
Espicom Business Intelligence Ltd, March 2010, Pages: 128
, migraine and osteoporosis. In the longer term, novel inhalation and intranasal drug candidates which are being developed now could greatly expand the therapeutic coverage of these drug delivery technologies
John Wiley and Sons Ltd, Jan 2011, Pages: 520
This book is a compilation of summarized analytical methods designed to serve the needs of pharmacologists, toxicologists, and other allied health professionals involved the development, use
Medical Letter, Jan 2011, Pages: 104
for Celiac Disease Patients
Issue 1282 (March 24, 2008)
- In Brief: Influenza Developments
- A Rivastigmine Patch for Dementia
- Palatal Implants for Snoring and Obstructive Sleep Apnea
Issue 1283 (April
Global Industry Analysts, Inc., Oct 2011, Pages: 560
and is expected to become mandatory in the rest of the world, in the next few years. The focus is also on developing needle-less injectors due to the rising numbers of needle stick injuries. More than a million
John Wiley and Sons Ltd, March 2008, Pages: 272
, the summary of its industrial development, the year put into practice, the biological target for the medicine, the human proteins related to the disease, the metabolism or action of the condition treated
Espicom Business Intelligence Ltd, Dec 2009, Pages: 318
The generic industry is known for producing ‘affordable medicines’. Cost has been an important factor in their development, particularly for oral drugs that are relatively cheap to produce and can be introduced
Lead Discovery, March 2003
in development or on the market for the treatment of migraine
Drug profiles
rizatriptan
sumatriptan
naratriptan
almotriptan
zolmitriptan
frovatriptan
eletriptan
dihydroergotamine
arotinolol
alpha
Espicom Business Intelligence Ltd, May 2009, Pages: 250
companies have started down the long road of drug discovery and branded product development.
With low-cost manufacturing, high-quality research and manufacturing facilities and educated personnel
Informa Healthcare, Jan 2007, Pages: 236
from supply of drug targets and chemical building blocks, through non-clinical development and on to clinical evaluation and regulatory affairs.
Innovation in the industry is not at a standstill
